Clinical Trial Update: Tirzepatide in Obesity-Driven Endometrial Cancer [EARLY_Phase 1]

View source ↗

Summary

An early phase 1 trial is evaluating tirzepatide for obesity-driven endometrial cancer and it is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Endometrial Cancer
• Obesity

Drugs mentioned

• MOUNJARO (tirzepatide)

Snippet

Sponsor: UNC Lineberger Comprehensive Cancer Center | Conditions: Endometrial Cancer, Obesity | EARLY_Phase 1 | Status: NOT_YET_RECRUITING